method for treating or preventing at least one inflammatory condition in a patient, method for inhibiting liver damage in a patient at risk of chemical liver damage from prescribed drugs or drugs of abuse, method for inhibiting nkt type i cell mediated tissue damage in a patient, method for inhibiting nkt type i cell activation, method for inhibiting nkt type i cell activation in a patient with an inflammatory disease, and method for inhibiting myeloid cell release in a patient's liver

摘要

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relates to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.